Pharvaris management commentary: Q3 2026 operating expenses rise 26% on IR launch preparations

• Pharvaris management commentary reported a nine-month net loss of €134.5 million through September 30, 2026, versus €129 million a year earlier.
• Research and development expenses rose 8% to €97.6 million, driven by higher personnel and clinical spending, partly offset by lower nonclinical costs.
• General and administrative expenses increased 49% to €47.6 million, reflecting commercial hiring and launch preparations for deucrictibant IR.
• Net finance income reached €11.8 million versus a €6.4 million expense, primarily reflecting a stronger US dollar against the euro.
• Operating cash outflow increased 30% to €128.8 million; cash and cash equivalents totaled €282.7 million at period-end.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-456847), on November 12, 2026, and is solely responsible for the information contained therein.